(R)-1-Benzyloxy-3-(4'-trifluoromethoxy-biphenyl-4-yloxy)-propan-2-ol | 220616-04-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-1-Benzyloxy-3-(4'-trifluoromethoxy-biphenyl-4-yloxy)-propan-2-ol
• 英文别名: (2R)-1-phenylmethoxy-3-[4-[4-(trifluoromethoxy)phenyl]phenoxy]propan-2-ol
• CAS: 220616-04-6
• 化学式: C₂₃H₂₁F₃O₄
• 分子量: 418.413
• InChiKey: MOUGFEVDGSEGNA-HXUWFJFHSA-N

物化性质

• 沸点：
  519.9±50.0 °C(predicted)
• 密度：
  1.254±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (R)-1-Benzyloxy-3-(4'-trifluoromethoxy-biphenyl-4-yloxy)-propan-2-ol 在 palladium on activated charcoal 氢气 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770

  摘要：

  Modification of the biphenyl portion of MMP inhibitor 2a gave analogue 2i which is greater than 1000-fold selective against MMP-2 versus MMP-1. The stereospecific synthesis of both enantiomers of 2i was achieved beginning with (S)- or (R)-benzyl glycidyl ether. The (S)-enantiomer, 11 (ABT-770), is orally bioavailable and efficacious in an in vivo model of tumor growth. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00032-4
• 作为产物：
  描述：

  对溴三氟甲氧基苯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三溴化硼 、 sodium carbonate 、 potassium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-1-Benzyloxy-3-(4'-trifluoromethoxy-biphenyl-4-yloxy)-propan-2-ol
  参考文献：
  名称：

  Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770

  摘要：

  Modification of the biphenyl portion of MMP inhibitor 2a gave analogue 2i which is greater than 1000-fold selective against MMP-2 versus MMP-1. The stereospecific synthesis of both enantiomers of 2i was achieved beginning with (S)- or (R)-benzyl glycidyl ether. The (S)-enantiomer, 11 (ABT-770), is orally bioavailable and efficacious in an in vivo model of tumor growth. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00032-4

文献信息

• Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770
  作者：Michael L. Curtin、Alan S. Florjancic、H.Robin Heyman、Michael R. Michaelides、Robert B. Garland、James H. Holms、Douglas H. Steinman、Joseph F. Dellaria、Jane Gong、Carol K. Wada、Yan Guo、Ildiko B. Elmore、Paul Tapang、Daniel H. Albert、Terrance J. Magoc、Patrick A. Marcotte、Jennifer J. Bouska、Carole L. Goodfellow、Joy L. Bauch、Kennan C. Marsh、Douglas W. Morgan、Steven K. Davidsen

  DOI：10.1016/s0960-894x(01)00032-4

  日期：2001.6

  Modification of the biphenyl portion of MMP inhibitor 2a gave analogue 2i which is greater than 1000-fold selective against MMP-2 versus MMP-1. The stereospecific synthesis of both enantiomers of 2i was achieved beginning with (S)- or (R)-benzyl glycidyl ether. The (S)-enantiomer, 11 (ABT-770), is orally bioavailable and efficacious in an in vivo model of tumor growth. (C) 2001 Elsevier Science Ltd. All rights reserved.